Preclinical Medications Screening in Dependence Models of Alcohol Use Disorder

This notice is related to Sources Sought Notice NIH-NICHD-2019-08, released on January 31, 2019. This acquisition is a full and open competition.

This notice is issued on behalf of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) by the National Institute of Child Health and Human Development (NICHD), Office of Acquisitions, NIH, DHHS. This is a Presolicitation Notice in advance of the Request for Proposals (RFP). The Government is not committed to award a contract pursuant to this announcement.

The RFP, NIH-NICHD-2019-08, detailing the specifics of the project, as well as information pertinent to the development of an Offeror's proposal, will be available electronically within 15 calendar days of this notice and may be accessed through the Internet on the Federal Business Opportunities (FBO) website: http://www.fedbizopps.gov. No paper solicitation is available. Potential Offerors are responsible for downloading the solicitation and for routinely checking the FBO website for any solicitation amendments issued by the Government. Proposals will be due on or about May 31, 2019. It is anticipated that a single cost-reimbursement contract award will be made for a 12-month base contract with four (4) option periods beginning on or about September 3, 2019.

This is a Research and Development contract requirement entitled, "Preclinical Medications Screening in Dependence Models of Alcohol Use Disorder". This is NOT an NIH grant opportunity.

The NIAAA seeks a contractor to address the present and anticipated future needs of NIAAA's Medications Development Program for the blind efficacy testing of reference and proprietary compounds in alcohol drinking mice made dependent through repeated cycles of ethanol vapor exposure and withdrawal. The Division of Neuroscience and Behavior's (DNB) Preclinical Medication Efficacy Testing Program seeks to support this effort and to implement the testing capacity of five (5) compounds per year over the next five (5) years using mechanisms having intellectual property conditions favorable to compound providers when acquiring compounds from industry. This will eliminate a major barrier to testing optimized compounds and will stimulate interest by the pharmaceutical industry in developing high quality, marketable compounds for alcoholism. The data generated will be used in the identification of compounds for further development.

It is anticipated that the effort to be supported will require an estimated 7,384 hours of effort in the base year and 29,536 in four (4) option periods. All qualified organizations are encouraged to respond with a contract proposal.

.